Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

From drugs to deprivation: a Bayesian framework for understanding models of psychosis.

Corlett PR, Frith CD, Fletcher PC.

Psychopharmacology (Berl). 2009 Nov;206(4):515-30. doi: 10.1007/s00213-009-1561-0. Epub 2009 May 28. Review.

2.

Glutamatergic model psychoses: prediction error, learning, and inference.

Corlett PR, Honey GD, Krystal JH, Fletcher PC.

Neuropsychopharmacology. 2011 Jan;36(1):294-315. doi: 10.1038/npp.2010.163. Epub 2010 Sep 22. Review.

3.

The endocannabinoid system as a target for modelling psychosis.

Koethe D, Hoyer C, Leweke FM.

Psychopharmacology (Berl). 2009 Nov;206(4):551-61. doi: 10.1007/s00213-009-1591-7. Epub 2009 Jun 16. Review.

PMID:
19529920
4.

Human Laboratory Studies on Cannabinoids and Psychosis.

Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M.

Biol Psychiatry. 2016 Apr 1;79(7):526-38. doi: 10.1016/j.biopsych.2016.01.011. Epub 2016 Feb 2. Review.

PMID:
26970363
5.

Modelling psychosis.

Curran HV, D'Souza DC, Robbins TW, Fletcher P.

Psychopharmacology (Berl). 2009 Nov;206(4):513-4. doi: 10.1007/s00213-009-1663-8. No abstract available.

PMID:
19756521
6.

Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis.

Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, Lee M, Pomarol-Clotet E, Murray GK, McKenna PJ, Robbins TW, Bullmore ET, Fletcher PC.

Arch Gen Psychiatry. 2006 Jun;63(6):611-21.

PMID:
16754834
7.

Cannabinoids and psychosis.

D'Souza DC.

Int Rev Neurobiol. 2007;78:289-326. Review.

PMID:
17349865
8.

Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Daumann J, Obradovic M, Kovar KA.

Neuropsychopharmacology. 2006 Feb;31(2):431-41.

9.
10.

Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?

Sharp FR, Hendren RL.

Epilepsy Behav. 2007 Jun;10(4):515-20. Epub 2007 Apr 6. Review.

11.

d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

De Gregorio D, Comai S, Posa L, Gobbi G.

Int J Mol Sci. 2016 Nov 23;17(11). pii: E1953. Review.

13.

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D.

Schizophr Bull. 2012 Sep;38(5):958-66. doi: 10.1093/schbul/sbs069. Review.

14.

Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?

Cancelli I, Beltrame M, D'Anna L, Gigli GL, Valente M.

Expert Opin Drug Saf. 2009 Sep;8(5):549-57. doi: 10.1517/14740330903099636. Review.

PMID:
19552610
16.

Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation.

Weiss SM, Whawell E, Upton R, Dourish CT.

Neurology. 2003 Dec 9;61(11 Suppl 6):S88-93. Review.

PMID:
14663018
17.

Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade.

Vinckier F, Gaillard R, Palminteri S, Rigoux L, Salvador A, Fornito A, Adapa R, Krebs MO, Pessiglione M, Fletcher PC.

Mol Psychiatry. 2016 Jul;21(7):946-55. doi: 10.1038/mp.2015.73. Epub 2015 Jun 9.

18.

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, Waberski TD, Gouzoulis-Mayfrank E.

Psychopharmacology (Berl). 2008 Jul;199(1):77-88. doi: 10.1007/s00213-008-1129-4. Epub 2008 May 18.

19.
20.

Serotonin research: contributions to understanding psychoses.

Geyer MA, Vollenweider FX.

Trends Pharmacol Sci. 2008 Sep;29(9):445-53. doi: 10.1016/j.tips.2008.06.006. Review.

PMID:
19086254

Supplemental Content

Support Center